Discover investment opportunities in Best Genome Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Genome Editing Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Genome Editing Stocks using our Smart AI Filter.
8 stocks found for "Best Genome Editing Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
2.51 | ±100.0% | -1.1 | 0.00% | |||
1.98 | ±100.0% | -2.4 | 0.00% | |||
1.92 | ±68.6% | -1.9 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.37 | ±22.9% | 21.1 | 0.52% | |||
1.39 | ±92.0% | -3.9 | 0.00% | |||
1.68 | ±83.0% | -0.6 | 0.00% | |||
1.82 | ±67.7% | -15.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why is CRISPR Therapeutics (CRSP) considered a leader in genome editing stocks?
A: CRISPR Therapeutics (CRSP) is acknowledged as a leader due to its pioneering use of CRISPR gene-editing technology, significant pipeline of clinical trials aimed at treating genetic disorders, and strategic partnerships with major pharmaceutical companies, enhancing its R&D capabilities.
Q: What differentiates Editas Medicine (EDIT) in the gene editing market?
A: Editas Medicine (EDIT) stands out by focusing on developing CRISPR technology for specific single-gene disorders, leveraging unique licensing of foundational gene-editing patents. This specialization involves collaborations with leading research institutions to advance its treatment platforms.
Q: How does Intellia Therapeutics (NTLA) approach genome editing differently from its competitors?
A: Intellia Therapeutics (NTLA) emphasizes in vivo applications of CRISPR technology, allowing direct gene editing within the body. Its proprietary delivery systems aim for targeted gene correction, differentiating it from ex vivo approaches taken by some competitors.
Q: Why might investors be interested in Beam Therapeutics (BEAM)?
A: Beam Therapeutics (BEAM) focuses on base editing technology that offers precision in genetic correction without causing double-strand breaks, potentially reducing off-target effects. This novel approach has piqued investor interest in non-disruptive genome editing solutions.
Q: What are the investment risks associated with Sangamo Therapeutics (SGMO)?
A: Sangamo Therapeutics (SGMO) faces risks typical of biotech firms, including regulatory hurdles, high R&D costs, and reliance on successful clinical trial outcomes. Market competition and technological advancements by peers may also impact its positioning.
Q: How might Poseida Therapeutics (PSTX) appeal to growth-focused investors?
A: Poseida Therapeutics (PSTX) appeals to growth-oriented investors with its proprietary genetic engineering platform, potentially addressing diverse disease areas. Its focus on CAR-T therapies offers promising avenues in oncology, bolstering long-term revenue growth prospects.